Back to search
Cytomegalovirus Cell Mediated Immunity
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Cytomegalovirus Cell Mediated Immunity trials may be worth asking aboutClinical trial pipeline · Data from ClinicalTrials.gov
See which Cytomegalovirus Cell Mediated Immunity trials may be worth asking aboutNorth America
Europe
Asia-Pacific
Rest of World
Trials may have sites in multiple countries. Filtering shows any trial with at least one site in the selected country.
Cytomegalovirus (CMV) reactivation is a common and serious complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and the reconstitu…
The goal of this laboratory research study is to learn if interrupting a patient's letermovir dosing based on their immune system response can help HSC transpla…
Cytomegalovirus (CMV) infection is a common complication in patients undergoing hematopoietic stem cell transplantation (SCT). Fixed-duration letermovir (LTV) p…
Cytomegalovirus (CMV) infection was observed in over 30% of organ recipients with high morbidity. Moreover, no prophylaxis, 75% R + D-transplanted, 55%, R + D +…